CLINICAL TRIALS
READ ABOUT THE TRIALS FOR YOURSELF.
Clinical Evaluation of Flosom for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia:
A Prospective Multicenter Study
This project contains the manuscript, supporting materials, and supplementary data for a prospective open-label clinical evaluation of Flosom®, a botanical formulation developed for men experiencing lower urinary tract symptoms associated with benign prostatic hyperplasia.
Serenoa repens extract in the treatment of benign prostatic hyperplasia:
One of the most frequently prescribed and studied agents is Serenoa repens extract, derived from the berry of the dwarf palm tree. This study aimed to review important published data regarding this type of treatment for benign prostatic hyperplasia.
Efficacy and Safety of Serenoa Repens Extract Among Patients With Benign Prostatic Hyperplasia:
A double blind, placebo-controlled study of 354 patients with LUTS/BPH from 19 institutions was conducted to evaluate the efficacy and safety of Serenoa repens.
Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation:
This study shows, for the first time, that CBD causes vasorelaxation of human mesenteric arteries via activation of CB1 and TRP channels, and is endothelium- and nitric oxide-dependent.
Cannabinoids Mediate Opposing Effects on Inflammation-Induced Intestinal Permeability:
The aim of the present study was to determine whether cannabinoids modulate the increased permeability associated with inflammation in vitro.